INDIA MARKET LENS

Dr. Reddy's Laboratories Limited (DRREDDY): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Dr. Reddy's Laboratories Limited, explained in plain English.

  • Dr. Reddy's Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • DRREDDY closed at ₹1,398.20 on 18 November 2026.
  • Over the past year the shares are up 12.4%, trading between ₹1,101.00 and ₹1,414.90.
  • Reported fundamentals show return on equity of 7.34%, a net margin of 8.48%, debt to equity of 18.57.
  • Our Pulse grade checklist scores it F (30/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 24.23% with a maximum drawdown of -17.45% and a beta of 0.44 against NIFTY 50.
  • Recent coverage: Stocks to watch: ITC, Lupin, NBCC, SBI, Dr Reddy's, Bosch, Ola Electric

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 18 Nov 2026. Market opens at 9:15 IST.

Dr. Reddy's Laboratories Limited (DRREDDY)

₹1,388

▲ 10.1 (+0.73%)

Price & volume

DRREDDY price chart, 1Y range. 252 points from 2025-11-20 to 2026-11-17. Opens at 1,248.6, closes at 1,388, ranging between 1,135.6 and 1,388.1,2001,3001,400Nov-25Jan-26Mar-26Apr-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Neutral momentum · 3/5
✓ Above 50-day avg✓ Above 200-day avgRSI 71.5 · overboughtMACD negativeBollinger %B 73ADX 40 · strong trend

1M

+12.57%

3M

+16.44%

6M

+3.84%

1Y

+11.54%

Where it sits in its 52-week range

100%
₹1,135.6₹1,388

Below 52-week high

0.0%

22.2% above the low

Momentum read

Neutral

3/5 checks passed

52-wk high

₹1,388

52-wk low

₹1,135.6

Market cap

₹1,15,713 Cr

P/E (trailing)

41.3

Dividend yield

—

ROE

7.34%

Profit margin

8.48%

Revenue growth

-1.5%

Price / Book

2.99

Debt / Equity

18.57

EPS (TTM)

33.59

Book value

₹463.56

Beta

0.44

Pulse grade: F, 30 out of 100

Momentum

B
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✕RSI in healthy 45-70 zone
  • ✓Positive 3-month return

Growth

F
  • ✕Revenue growth above Pharma & Healthcare median (20.8%)
  • ✕Revenue growing above 5%
  • ✕Quarterly profits trending up

Profitability

F
  • ✕Return on equity above Pharma & Healthcare median (14.64%)
  • ✕Return on equity above 12%
  • ✕Profit margin above Pharma & Healthcare median (13.82%)

Safety

D
  • ✕Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹8,671 crore · net profit ₹925 crore · margin 10.7%

8,8050Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,870+0.13%-6.55%
CIPLA1,388-0.47%-9.61%
DIVISLAB11,150+0.63%-3.59%
APOLLOHOSP8,712.5-0.67%-3.93%
LUPIN1,950-1.35%-22.46%
AUROPHARMA1,794.1+0.01%-3.30%

DRREDDY headlines

No DRREDDY stories right now.

DRREDDY filings & announcements

Reading the exchange…

DRREDDY, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

24.22%

Sharpe ratio

0.3

Sortino ratio

0.49

Max drawdown

-17.45%

Daily VaR (95%)

-1.98%

CAGR (1Y)

11.21%

Return skew

1.28

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.